Local Pittsburgh program “Our Regions Business” features ALung.
Christiana Care Health System is participating in national research that may provide a non-invasive alternative to a ventilator for patients with severe chronic obstructive pulmonary disease (COPD).
PITTSBURGH--(BUSINESS WIRE)--ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of a major milestone with the enrollment of the 50th patient in its U.S. based VENT-AVOID clinical trial.
Coeo, a commercial real estate technology platform, has added a new member to its leadership.
Cognition Therapeutics Inc. has received a $3.3 million grant from the National Institute of Aging to conduct a clinical trial on Alzheimer's disease.
PITTSBURGH--(BUSINESS WIRE)--ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of a major milestone in its U.S. based VENT-AVOID clinical trial and reports continued progress in its clinical trial programs.
Biologics therapies have the promise to revolutionize orthopedics and sports medicine, but unauthorized operators pose a serious threat to emerging therapies.
Pittsburgh, PA – Edge Case Research (Edge Case), founded by the recognized world leaders in autonomous system safety and autonomous vehicle safety, announced it secured $7 million in investment funding. The investment will expand the development of Hologram, an intelligent safety assessment platform for autonomous vehicle software that operates at the speed of modern machine learning development.
SAN DIEGO, CA AND WASHINGTON, DC, FEBRUARY 26, 2019 (GLOBE NEWSWIRE) ‐‐ Exagen, a life science company serving the rheumatology specialty, and the Lupus Foundation of America, the national force devoted to solving the mystery of lupus, announced a new initiative to educate those at risk for lupus about the disease and its symptoms in an effort to reduce the time it can take for an accurate lupus diagnosis.
Pittsburgh, April 05, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced that Mary Sano, Ph.D. of Mount Sinai School of Medicine and Philip Scheltens, M.D., Ph.D. of the VU Medical Center (VUmc) Alzheimer’s Center in Amsterdam have accepted appointments to the Company’s Medical Advisory Board.